These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 2870089

  • 1. Depot neuroleptics: side effects and safety.
    Marder SR.
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [Abstract] [Full Text] [Related]

  • 2. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM, Kane JM.
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [Abstract] [Full Text] [Related]

  • 3. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM.
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Experience with depot neuroleptics in ambulatory practice.
    Fiolet J.
    Acta Psychiatr Belg; 1981 Feb; 81(2):182-8. PubMed ID: 6117188
    [Abstract] [Full Text] [Related]

  • 6. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA.
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [Abstract] [Full Text] [Related]

  • 9. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC.
    Clin Neuropharmacol; 1991 May; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [Abstract] [Full Text] [Related]

  • 10. Eleven years of experience with depot neuroleptics.
    Gross H, Kaltenbäck E, Pfolz H.
    Acta Psychiatr Belg; 1981 May; 81(2):128-32. PubMed ID: 6117183
    [Abstract] [Full Text] [Related]

  • 11. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 12. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
    Barnes TR.
    Psychiatr Dev; 1987 Jul; 5(4):301-19. PubMed ID: 2895467
    [Abstract] [Full Text] [Related]

  • 13. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ, Kissling W.
    Clin Neuropharmacol; 1986 Jul; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract] [Full Text] [Related]

  • 14. [Effects and side effects of depot neuroleptics as perceived by patients].
    Trenckmann U.
    Psychiatr Prax; 1990 Sep; 17(5):184-7. PubMed ID: 1980015
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C, Seeman MV, Seeman P.
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacologic treatment of schizophrenia.
    Levinson DF.
    Clin Ther; 1991 Jan; 13(3):326-52. PubMed ID: 1683269
    [Abstract] [Full Text] [Related]

  • 20. Prevention and management of tardive dyskinesia.
    Jeste DV, Wyatt RJ.
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):14-8. PubMed ID: 2858473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.